Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$0.28 USD
+0.01 (2.46%)
Updated Jun 28, 2024 03:47 PM ET
After-Market: $0.28 +0.01 (1.82%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Galmed Pharmaceuticals Ltd. [GLMD]
Reports for Purchase
Showing records 141 - 160 ( 192 total )
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Give Credit Where Credit Is Due; Initiating with Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
3Q Recap: Major Catalysts From Aramchol Data in 1H18: ARRIVE and ARREST; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Healthcare - Weekly NASH Newsletter: MRI-PDFF Is The New Favorite Toy In NASH Playground
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Post-AASLD KOL Presentation Highlights Aramchol''s Unique MOA; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
2Q Recap: Aramchol to ARRIVE and ARREST in 1H18; Raising PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
We are dropping coverage of GLMD shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
1Q17 Recap: Pre-Clinical Data Demonstrates Aramchol''s Anti-fibrotic Activity; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
4Q16 Recap: ARREST Data in 2Q18; Anti-Fibrotic Data at EASL; PT to $12 on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
3Q16 Recap: ARREST Enrollment Accelerates; Completion Appears Likely by Year End; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
New CSO Highlights the Aim of Pursuing New Indications, Perhaps Beyond the Liver
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Meaningful Risk of Enrollment Delay for ARREST; Maintain Buy and Reduce PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
The NASH Waiting Game: Resuming Coverage with a Buy and a $6 Price Target
Provider: Roth Capital Partners, Inc.
Analyst: YANIV S